



Press release |

Regulated information

IBA ANNOUNCES NEW CHIEF OPERATING OFFICER AND LEADERSHIP SUCCESSION PLAN

Louvain-La-Neuve, Belgium, Jan. 09, 2012 —IBA (Ion Beam Applications S.A.) announces that Olivier Legrain, current Chief Strategic Officer, takes on, as of today, the role of Chief Operating Officer as part of a plan to make him succeed Pierre Mottet as CEO upon the upcoming shareholder meeting on May 9.

Pierre Mottet will then be appointed vice-chairman of the board under the plan to make him succeed Jean Stephenne as chairman of the Board upon the end of Mr. Stephenne's mandate in May 2013.

Pierre Mottet (50) has decided to add new activities and challenges to his professional and private life. However from his Board's position, he will continue to provide IBA with his experience, industry knowledge and network based on his successful 24 year stint at IBA. Under Pierre Mottet's leadership, the company has developed into an international group of 2,100 professionals recognized for their leadership in cancer diagnostics and therapy and posting revenues of around EUR 400 million.

Olivier Legrain (43) joined the company in 1996 as financial controller. He then developed as President of IBA Dosimetry business from 1999 to 2003, President of IBA Molecular business from 2003 till 2010 and Chief Strategy Officer thereafter.

"Based on his long experience at IBA, Olivier understands immediately and fully the complexities and challenges of the Company. He is in a unique position to support the company's ongoing growth and strategic initiatives with a strong financial discipline. We have been preparing for him to take the job for many months." Jean Stephenne said.

"Olivier has impressed us by his strategic vision first in dosimetry and then at a much larger scale in developing IBA roadmap and leadership in molecular imaging resulting in our partnership with SK Capital. Just as impressive was his capability to lead our teams to execute the strategy in the many cultures he has operated including Sweden, Germany, Belgium, France and the US. He is obsessed by customer delight, efficiency and IBA values. I am very confident that under his leadership, IBA will continue to grow and prosper" Pierre Mottet added.

ABOUT IBA

IBA group develops and markets leading edge technologies for healthcare with a focus on cancer diagnosis and therapy. The company is listed on the pan-European stock exchange EURONEXT, IBA is included in the BelMid Index. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). Website: www.iba-worldwide.com

CONTACT - Sandrine Leriche

VP Corporate Communication

Phone : +32 10 47 58 90

E-mail : Sandrine.leriche@iba-group.com